<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734691</url>
  </required_header>
  <id_info>
    <org_study_id>OPAC study</org_study_id>
    <nct_id>NCT04734691</nct_id>
  </id_info>
  <brief_title>Second Line Oxaliplatin Based Chemotherapy Alone Versus Oxaliplatin Based PIPAC and Chemotherapy in Colorectal Peritoneal Carcinomatosis : A Phase II Randomize Mutli-centric Study</brief_title>
  <acronym>OPAC</acronym>
  <official_title>Second Line Oxaliplatin Based Chemotherapy Alone Versus Oxaliplatin Based PIPAC and Chemotherapy in Colorectal Peritoneal Carcinomatosis : A Phase II Randomize Mutli-centric Study : OPAC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sleiman Marwan-Julien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is the third most common cancer in men and second in women. It represent&#xD;
      345'346 new cases per year in Europe and 134'349 in the United States of America. The&#xD;
      peritoneal cavity is the second most frequent site, after liver, for colorectal cancer&#xD;
      relapse.Peritoneal carcinomatosis (PC) is found in approximately 5 % of patients diagnosed&#xD;
      with colorectal cancer and 24% of patients with synchronous metastasis at the time of&#xD;
      diagnosis. Eight percent of colorectal cancer patient will develop PC during the course of&#xD;
      their disease .&#xD;
&#xD;
      Currently systemic chemotherapy is the standard of care for the treatment of unresectable&#xD;
      peritoneal carcinomatosis from colorectal cancer with a median survival rate of 16.3 months&#xD;
      Peritoneal carcinomatosis has a poor response to systemic chemotherapy due to a weak&#xD;
      penetration of agents into the peritoneum.&#xD;
&#xD;
      A new approach of intraperitoneal carcinomatosis is now developed: Pressurized&#xD;
      intraperitoneal aerosol chemotherapy (PIPAC) is used to deliver intraperitoneal chemotherapy.&#xD;
      It enhances the effect of chemotherapy because of the physical properties of aerosol and&#xD;
      pressure.&#xD;
&#xD;
      PIPAC is a safe with a 23% morbidity and tolerated technic that is now well described.&#xD;
&#xD;
      We want to conduct a study to prove or infirm the superiority of PIPAC associated with&#xD;
      systemic chemotherapy compare to systemic chemotherapy alone in peritoneal carcinomatosis&#xD;
      from colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>8 months</time_frame>
    <description>any clinical sign and/or morphological sign of peritoneal recurrence or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life C30</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PIPAC</intervention_name>
    <description>PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 &lt; age ≤ 75 years old with Performance status (WHO) ≤ 2 Histologically&#xD;
             evidenced synchronous or metachronous PM of a colorectal cancer with a PCI ≥ 15 (No&#xD;
             complete resectable PC) Histologically evidenced synchronous or metachronous PM of a&#xD;
             colorectal cancer with a PCI &lt; 15 + liver or pulmonary unresectable metastases PCI &lt;&#xD;
             15 but with progression at the restaging after the first line of chemotherapy&#xD;
             Unresectable peritoneal relapse secondary to cytoreduction surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically significant ascites (&gt; 3000 cc)&#xD;
&#xD;
          -  Pleural effusion requiring evacuation for respiratory failure&#xD;
&#xD;
          -  Small bowel occlusion with no possible food intake&#xD;
&#xD;
          -  Presence of comorbidities, notably serious chronic diseases or organ failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marwan-Julien Sleiman</last_name>
    <phone>0041795533197</phone>
    <email>marwan.sleiman@hcuge.ch</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Sleiman Marwan-Julien</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

